Showing 1 - 8 of 8
Persistent link: https://www.econbiz.de/10001554889
This paper examines how a radical technological innovation affects alliance formation of firms and subsequent network structures. We use longitudinal data of interfirm R&D collaborations in the biopharmaceutical industry in which a new technological regime is established. Our findings suggest...
Persistent link: https://www.econbiz.de/10011257059
This paper examines how a radical technological innovation affects alliance formation of firms and subsequent network structures. We use longitudinal data of interfirm R&D collaborations in the biopharmaceutical industry in which a new technological regime is established. Our findings suggest...
Persistent link: https://www.econbiz.de/10010325532
This paper examines how a radical technological innovation affects alliance formation of firms and subsequent network structures. We use longitudinal data of interfirm R&D collaborations in the biopharmaceutical industry in which a new technological regime is established. Our findings suggest...
Persistent link: https://www.econbiz.de/10005137005
This paper examines how a radical technological innovation affects alliance formation of firms and subsequent network structures. We use longitudinal data of interfirm R&D collaborations in the biopharmaceutical industry in which a new technological regime is established. Our findings suggest...
Persistent link: https://www.econbiz.de/10011372508
Persistent link: https://www.econbiz.de/10001734783
In the current COVID-19 pandemic, we witness sharp fluctuations of biopharmaceutical equity prices as a response to innovation related news. On 23.04.2020, the stock price of Biotech firm Gilead Sciences fell by as much as 9% after rumors suggested that remdesivir, its experimental COVID-19...
Persistent link: https://www.econbiz.de/10012835469
Persistent link: https://www.econbiz.de/10003908978